title: [Ipilimumab, a new molecular targetted therapy of malignant neoplastic disease].
abstract: Ipilimumab is a fully human monoclonal antibody that binds to CTLA-4(cytotoxic T lymphocyte-associated antigen 4). It is intended to be used as a drug to activate the immune system by binding to CTLA-4, which suppresses T-cells in natural immune responses. Recently, a phase III , multi-center, randomized, double-blind, clinical study showed an improvement in over-all/progression-free survival in patients with advanced melanomas. Ipilimumab is undergoing clinical trials for the treatment of melanoma, non-small cell lung cancer(NSCLC), small cell lung cancer(SCLC)and metastatic hormone-refractory prostate cancer, as well as other neoplastic diseases.
authors.affiliation: Tohoku University Hospital Cancer Center, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Mori
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D000074324:Ipilimumab; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab